Clinical Report: Revisions to the Global Initiative for Asthma's Diagnostic Criteria for Adult Asthma
Overview
Recent updates to the GINA diagnostic criteria for asthma have significantly improved sensitivity while reducing specificity. The removal of airflow limitation as a mandatory criterion and the inclusion of type 2 inflammatory biomarkers have altered the diagnostic landscape for adult asthma.
Background
Accurate diagnosis of asthma is crucial for effective management and treatment. The GINA guidelines are widely utilized in clinical practice, and revisions to these guidelines can impact the identification of asthma cases. Understanding the implications of these changes is essential for healthcare professionals to avoid misdiagnosis and ensure appropriate patient care.
Data Highlights
Criteria
Sensitivity
Specificity
GINA 2023
47%
100%
GINA 2024
67%
96%
GINA 2025
57%
88%
Key Findings
The removal of airflow limitation (AFL) in GINA 2024 increased asthma diagnoses from 27% to 63%.
Incorporating type 2 inflammatory biomarkers in GINA 2025 improved sensitivity but reduced specificity.
Overall specificity increased from 46% to 96% between 2023 and 2025, while sensitivity decreased from 100% to 67%.
Fractional exhaled nitric oxide and blood eosinophil counts are effective biomarkers for type 2 inflammation.
Changes in GINA guidelines shifted the diagnostic approach from a “rule-in” to a “rule-out” strategy for asthma.
Clinical Implications
Clinicians should be aware of the revised GINA guidelines to enhance diagnostic accuracy for asthma. The increased sensitivity may lead to more diagnoses, but the reduced specificity necessitates careful consideration to avoid overdiagnosis.
Conclusion
The revisions to the GINA diagnostic criteria represent a significant shift in asthma diagnosis, emphasizing the need for clinicians to adapt their practices accordingly to ensure accurate patient assessment.
